Literature DB >> 30316993

Giant-cell arteritis-related mortality in France: A multiple-cause-of-death analysis.

Thibaud Chazal1, Raphael Lhote1, Grégoire Rey2, Julien Haroche3, Mireille Eb2, Zahir Amoura3, Fleur Cohen Aubart4.   

Abstract

OBJECTIVES: Giant-cell arteritis (GCA) is a large vessel vasculitis. Data regarding mortality are controversial. We describe the mortality data of the French death certificates for the period of 2005 to 2014.
METHODS: Using multiple-cause-of-death (MCOD) analysis, we calculated age-adjusted mortality rates for GCA, examined differences in mortality rates according to age and gender and analyzed the underlying causes of death (UCD).
RESULTS: We analyzed 4628 death certificates listing a diagnosis of GCA as UCD or non-underlying cause of death (NUCD). The mean age of death was 86 (±6.8) years. The overall age-standardized mortality rate among GCA patients was 7.2 per million population. Throughout the study period, the mean age of death was significantly increased (r = 0.17, p < .0001) in both genders. There was no significant difference with age repartition of death in the general population (p = .26). When GCA was listed as the UCD, most frequent associated diseases were cardiovascular (79%) and infectious diseases (35%). When GCA was reported as the NUCD, the listed UCD was a cardiovascular event in 40% of cases, neoplasm in 13%, neurodegenerative disorder in 11% and infectious disease in 10%. When GCA was the UCD or NUCD, an age-adjusted observed/expected ratio > 1 in GCA-associated mortality compared with the general population mortality was observed for tuberculosis, pneumonia and cardiovascular diseases.
CONCLUSION: In this analysis of French death certificates mentioning GCA, we observed a stable standardized mortality rate between 2005 and 2014. The most frequent associated diseases were cardiovascular diseases and infections.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Epidemiology.; Giant—cell arteritis; Mortality

Mesh:

Year:  2018        PMID: 30316993     DOI: 10.1016/j.autrev.2018.06.012

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  5 in total

Review 1.  Aging in Primary Systemic Vasculitis: Implications for Diagnosis, Clinical Manifestations, and Management.

Authors:  Alvise Berti; Roberto Caporali; Carlomaurizio Montecucco; Giuseppe Paolazzi; Sara Monti
Journal:  Drugs Aging       Date:  2019-01       Impact factor: 3.923

Review 2.  Neurologic manifestations of giant cell arteritis.

Authors:  Antoine Soulages; Igor Sibon; Jean-Michel Vallat; Emmanuel Ellie; Frédéric Bourdain; Fanny Duval; Louis Carla; Marie-Laure Martin-Négrier; Guilhem Solé; Charles Laurent; Agnès Monnier; Gwendal Le Masson; Stéphane Mathis
Journal:  J Neurol       Date:  2022-02-06       Impact factor: 4.849

Review 3.  Looking ahead: giant-cell arteritis in 10 years time.

Authors:  Milena Bond; Alessandro Tomelleri; Frank Buttgereit; Eric L Matteson; Christian Dejaco
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-05-24       Impact factor: 3.625

4.  Patients' Baseline Characteristics, but Not Tocilizumab Exposure, Affect Severe Outcomes Onset in Giant Cell Arteritis: A Real-World Study.

Authors:  Cyril Dumain; Jonathan Broner; Erik Arnaud; Emmanuel Dewavrin; Jan Holubar; Myriam Fantone; Benoit de Wazières; Simon Parreau; Pierre Fesler; Philippe Guilpain; Camille Roubille; Radjiv Goulabchand
Journal:  J Clin Med       Date:  2022-05-31       Impact factor: 4.964

Review 5.  Aging-Related Vascular Inflammation: Giant Cell Arteritis and Neurological Disorders.

Authors:  Ryu Watanabe; Motomu Hashimoto
Journal:  Front Aging Neurosci       Date:  2022-04-12       Impact factor: 5.702

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.